Compare Neurocrine Biosciences Inc (NBIX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Quantumscape Corp — how do they compare? Neurocrine Biosciences Inc trades at $156 (market cap $16.46B), while Quantumscape Corp trades at $6.39 (market cap $3.90B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.2× Quantumscape Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| NBIX | QS | |
|---|---|---|
Market Cap | $16.46B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $18.44 |
52-Week Low | $123.10 | $4.89 |
Enterprise Value | $16.48B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
QuantumScape (QS) trades at $6.335, up 2.34% today, with a bullish technical signal from moving averages but overbought RSI readings. The company remains pre-revenue, reporting a net loss of $435.05M in 2025, with negative ROE and ROA. Recent news highlights delays in commercialization to 2029 and mixed institutional activity, while Q2 2026 earnings beat estimates but triggered a stock sell-off.
The outlook is highly speculative, hinging on successful solid-state battery commercialization by 2029. Investment opportunity lies in disruptive technology potential with automotive partners like Volkswagen, but risks include persistent losses, funding needs, and intense competition. Analyst sentiment is cautious, with no buy ratings and a majority hold recommendation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
